Sucampo Pharma Cash Flow - Annual (NASDAQ:SCMP)

Add to My Stocks
$18 $0 (0%) SCMP stock closing price Feb 13, 2018 (Closing)

For analyzing any company like Sucampo Pharma from an investment perspective, its important to check the cash flow statement. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Sucampo Pharma profits and Sucampo Pharma debt. The cash flow statement is essetial while conducting the Sucampo Pharma cash flow analysis and can be used to measure the operating performance of Sucampo Pharma compared to various industry peers like CNTTF stock and RDUS stock. Sucampo Pharma had an inflow of $8.31M from operating activities, $70.53M inflow due to financing activities, and $-1.84M outflow due to investing activities for 2016.

View details of Sucampo Pharma cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201620152014201320122011201020092008
Net Income Cash Flow
18.48M33.37M13.12M6.41M4.83M-17.3M-2.75M-0.76M24.95M
Depreciation Depletion Amortization Cash-Flow45.68M10.7M1.17M1.59M1.55M1.95M2.58M2.17M-
Net Increase (Decrease) in Assets Liabilities-32.84M-14.67M--10.94M1.75M-4.73M-4.33M-2.94M15.14M
Cash From (used in) Discontinued Operations---------
Other Adjustments Net-23.01M-10.81M16.53M-2.49M3.85M-1.16M--3.35M
Net Cash from (used by) Operating Activities
8.31M18.58M30.87M-5.41M12M-19.99M-3.35M-0.8M37.19M
Increase (Decrease) in Prop Plant And Equipment-1.22M-3.55M-0.06M-0.16M-0.43M-0.25M-0.32M-0.49M-0.45M
Acquisition Disposition of Subsidiaires--161.18M-----28.11M--
Increase (Decrease) in Investments-5.25M35.84M-12.8M-2.88M4.93M33.44M31.49M-32.04M-52.09M
Other Cash Inflow (Outflow) from Investment Activities4.63M-2.24M25.82M-10.82M-5.08M-5.28M-14.9M-2.91M-
Net Cash from (used by) Investment Activities
-1.84M-131.15M12.95M-13.88M-0.58M27.9M-11.85M-35.45M-52.54M
Issuance (Purchase) of Equity Shares6.21M-38.2M9.15M7.3M-0.94M-0.58M---
Issuance (Repayment) of Debt Securities20.58M227.67M-24.9M3.06M-7.5M-7.5M12.07M--
Increase (Decrease) in Bank & Other Borrowings---------
Payment of Dividends & Other Cash Distributions-------13.72M--
Other Cash from (used by) Financing Activities43.73M-40.12M-------
Net Cash from (used by) Financing Activities
70.53M149.34M-15.41M10.58M-8.44M-8.08M-1.63M--
Effect of Exchange Rate Changes on Cash13.02M-0.11M-0.9M--1.6M1.59M4.66M--
Net Change in Cash & Cash Equivalents
90.02M36.66M27.52M-7.92M1.36M1.41M-12.17M-35.84M-14.02M
Cash & Equivalents at Beginning of Year108.28M71.62M44.1M52.02M50.66M49.24M61.42M62.56M25.55M
Cash & Equivalents at Year End198.3M108.28M71.62M44.1M52.02M50.66M49.24M26.71M11.53M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

While Sucampo Pharma stock price history provides the price history of a stock, Sucampo Pharma stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Sucampo Pharma has cash of $198.3M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Sucampo Pharma stock price.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Sucampo Pharma gained $8.31M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $-1.84M for SCMP in last 2016 report.
  • Cash flow from financing activities shows the flow of cash between Sucampo Pharma and its owners and creditors and was $70.53M for 2016. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Sucampo Pharma Cash Flow

Annual Cash Flow Statements For Sucampo Pharmaceuticals, Inc. Peers

Cumberland Pharma cash flow, Nektar Therapeutics cash flow, Radius Health cash flow, Takeda Pharma cash flow